This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:
- pricing and product initiatives of competitors;
- legislative and regulatory developments and economic conditions;
- delay or inability in obtaining regulatory approvals or bringing products to market;
- fluctuations in currency exchange rates and general financial market conditions;
- uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
- increased government pricing pressures;
- interruptions in production;
- loss of or inability to obtain adequate protection for intellectual property rights;
- litigation;
- loss of key executives or other employees; and
- adverse publicity and news coverage.
Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.
For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
Roche
Q1 2025 sales
Basel, 24 April 2025
Group
Thomas Schinecker Chief Executive Officer
Performance
Outlook
Q1 2025: Group sales growth at +6%
Q1 sales all at CER
- Group sales growth +6%, +8% Pharma and 0% for Diagnostics (healthcare pricing reforms in China)
- LOE impact in line with guidance
Key milestones achieved in Q1
- Pharma regulatory: EU approval Columvi in 2L+ DLBCL, US approval Susvimo in DME and TNKase in acute ischemic stroke, US & EU filing Gazvya in LN, EU filing Lunsumio SC in 3L+ FL
- Pharma readouts: Positive Ph III (SUNMO) Lunsumio + Polivy in 2L+ DLBCL
- Ph III decisions taken: trontinemab in AD (data presented at ADPD), NXT007 in Hemophilia A (data to be presented at upcoming medical conference)
- Business development: Zealand Pharma collaboration on petrelintide (long-acting amylin analog)*
- Diagnostics regulatory: cobas liat CT/NG
- Diagnostics pipeline: Unveiling of novel SBX sequencing technology
Significant newsflow in 2025 ahead
- Pivotal Ph III readouts: giredestrant in 1L ER+/HER2- mBC and in post CDKi ER+/HER2- mBC, Lunsumio in 2L+ FL, Venclexta in 1L MDS, PiaSky in aHUS, Ocrevus HD in PPMS, fenebrutinib in RMS and PPMS, astegolimab in COPD, Gazyva in SLE, vamikibart in UME
- Ph III enabling readouts: Evrysdi + GYM 329 in SMA, GYM 329 in FSHD, zilebesiran in HTN, CT-388 in obesity, CT-868 in T1D
- Diagnostics launches: Elecsys pTau181, Elecsys Troponin-T hs Generation 6, Elecsys Pro-C3 ADAPT, cobas i601 Mass Spectrometry wave 1 ipacks, cobas BV/CV, navify Digital Pathology 3.0, Elecsys Dengue Ag
*pending deal closure; LOE: Loss of exclusivity includes global losses of Avastin, Herceptin, MabThera/Rituxan, Esbriet, Lucentis and Actemra; CER: Constant Exchange Rates (avg. full year 2024); AD: | |
Alzheimer's disease; SC: subcutaneous; ER: Estrogen-receptor; HER2: Human epidermal growth factor; mBC: Metastatic breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follicular lymphoma; MDS: | |
Myelodysplastic syndromes; aHUS: Atypical hemolytic uremic syndrome; HD: High dose; RMS/PPMS: Remitting/primary progressive multiple sclerosis; COPD: Chronic obstructive pulmonary disease; SLE: | |
Systemic lupus erythematosus; UME: Uveitic macular edema; SMA: Spinal muscular atrophy; FSHD: Facioscapulohumeral muscular dystrophy; HTN: hypertension; LN: Lupus nephrits | 6 |
Q1 2025: Strong Pharma sales driving Group growth
Diagnostics impacted by healthcare pricing reforms in China
Q1 2025 | Q1 2024 | Change in % | ||
CHFbn | CHFbn | CHF | CER | |
Pharmaceuticals Division | 11.9 | 10.9 | 9 | 8 |
Diagnostics Division | 3.5 | 3.5 | 0 | 0 |
Roche Group | 15.4 | 14.4 | 7 | 6 |
CER: Constant Exchange Rates (avg full year 2024) | 7 |
Q1 2025: Consistent strong growth in the last four quarters
Group sales growth
%CER | ||||||||||||||
+15% | China Diagnostics | |||||||||||||
+10% | +9% | +9% | +9% | +9% | healthcare pricing reforms | |||||||||
+6% | ||||||||||||||
+5% | +2% | +1% | +2% | |||||||||||
+1% | ||||||||||||||
0% | ||||||||||||||
COVID-19 pandemic | Pandemic phase out | Post-pandemic | ||||||||||||
-5%2020 | Base business: +1%* | Base business: +8%* | Business growth: +8%* | |||||||||||
2021 | 2022 | 2023 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 |
*Average growth rate of quarterly CER growth rates for specified period; All growth rates at Constant Exchange Rates (avg. full year of respective years); Base business: Pharma excluding Ronapreve | |
and Diagnostics excluding COVID-19 diagnostic tests | 8 |
Key growth drivers of the Roche portfolio
Diagnostics: Molecular Lab and
Pathology Lab driving growth; China impacted by healthcare pricing reforms
0% | Q1 2025 sales | |
(CHFbn, YoY CER growth) | ||
3.5 | Phesgo: Conversion rate climbing to 47% | |
Alecensa: Geographic expansion in adj. ALK+ NSCLC | ||
6.0 +6%
Vabysmo: Continued market share
expansion, incl. naïve pts; US impacted
by branded market contraction
0.9 CHF 15.4bn
+17% 1.1
1.6
Columvi: EU approval in 2L+ DLBCL (STARGLO)
Lunsumio+Polivy: Positive Ph III (SUNMO) in 2L+ DLBCL Hemlibra: Next-gen bispecific NXT007 to enter Ph III
Xolair: >50k patients on treatment for
food allergy
+8%
2.4
+10% Ocrevus Zunovo: Permanent J-Code granted April 1st Evrysdi: US approval for tablet formulation achieved
Oncology/Hematology | Immunology | Other Pharma | ||
Neurology | Ophthalmology | Diagnostics | ||
CER: Constant Exchange Rate (avg. full year 2024); ALK: Anaplastic lymphoma kinase; NSCLC: Non-small cell lung cancer; DLBCL: Diffuse large B-Cell lymphoma | 9 |
Young portfolio to drive growth in the near- to mid-term
4 key pivotal NME readouts expected in 2025
CHFbn
% of Pharma Sales2
2015 2016
2017
2018
2019
2020
2021
2022
2023
1
2024
2025
8.0
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
59%
50%55%
42%
Pivotal NME readouts
- astegolimab in COPD
- vamikibart in UME
- giredestrant in ER+/HER2- BC
- fenebrutinib in RMS/PPMS
Q1 2022 | Q1 2023 | Q1 2024 | Q1 2025 | |
Cotellic | Alecensa | Tecentriq | Ocrevus | Hemlibra |
Luxturna | Xofluza | Polivy | Rozlytrek | Enspryng |
Phesgo | Evrysdi | Ronapreve | Susvimo | Vabysmo |
Lunsumio | Columvi | Elevidys | Piasky | Itovebi |
Young portfolio defined as all launches since end of 2015; 1. Elevidys: Accelerated US approval by partner company Sarepta; 2. Venclexta sales booked by AbbVie and therefore not included; NME: New molecular entity; COPD: | |
Chronic obstructive pulmonary disorder; RMS/PPMS: Relapsing/primary progressive multiple sclerosis; ER: Estrogen receptor; HER2: Human epidermal growth factor 2 receptor; BC: Breast cancer; UME: Uveitic macular edema | 10 |
Attachments
- Original document
- Permalink
Disclaimer
Roche Holding AG published this content on April 24, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 24, 2025 at 07:51 UTC.
